STOCK TITAN

Director Roberto Mignone gains Guardant (GH) shares through RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Guardant Health director Roberto Mignone reported a routine vesting of equity awards. On 01/21/2026, 264 Restricted Stock Units converted into 264 shares of Guardant Health common stock at an exercise price of $0 per share, increasing his directly held common stock to 3,959 shares. The related RSU award, granted on November 8, 2024, vests over four years: 25% of the shares vested on the one-year anniversary of 10/21/2024, and the remaining 75% vests in equal monthly installments over the following three years. After this vesting event, Mignone directly holds 8,712 RSUs in addition to his common shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MIGNONE ROBERTO

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/21/2026 M 264 A $0 3,959 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 01/21/2026 M 264 (1) (2) Common Stock 264 $0 8,712 D
Explanation of Responses:
1. The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter.
2. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Roberto A. Mignone 01/22/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did GH director Roberto Mignone report?

Director Roberto Mignone reported a vesting event in which 264 Restricted Stock Units converted into 264 shares of Guardant Health common stock on 01/21/2026 at an exercise price of $0 per share.

How many Guardant Health (GH) shares does Roberto Mignone hold after this transaction?

Following the reported transaction, Roberto Mignone directly owns 3,959 shares of Guardant Health common stock, in addition to his remaining unvested and unexercised equity awards.

How many Restricted Stock Units does Roberto Mignone still hold in GH?

After the 01/21/2026 vesting, Mignone directly holds 8,712 Restricted Stock Units related to Guardant Health common stock.

What is the vesting schedule for Roberto Mignone’s November 8, 2024 RSU grant at Guardant Health?

The RSU award granted on November 8, 2024 vests over four years: 25% vested on the one-year anniversary of 10/21/2024, and the remaining 75% vests monthly over the subsequent three-year period.

What transaction code is used for this GH insider RSU vesting and what does it represent?

The transaction is reported with code M, indicating the exercise or conversion of a derivative security. In this case, 264 Restricted Stock Units converted into 264 shares of common stock at $0 per share.

Is Roberto Mignone’s ownership in GH reported as direct or indirect?

The filing shows direct ownership (D) for both the 3,959 shares of common stock and the 8,712 Restricted Stock Units, with no separate entity listed for indirect ownership.

Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

15.23B
123.56M
4.5%
99.11%
6.43%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO